Abstract
Our understanding of Alzheimer’s disease (AD) has transformed from a purely neuronal perspective to one that acknowledges the involvement of glial cells. Despite remarkable progress in unraveling the biology of microglia, astrocytes and vascular elements, the exploration of oligodendrocytes in AD is still in its early stages. Contrary to the traditional notion of oligodendrocytes as passive bystanders in AD pathology, emerging evidence indicates their active participation in and reaction to amyloid and tau pathology. Oligodendrocytes undergo a functional transition to a disease-associated state, engaging in immune modulation, stress responses and cellular survival. Far from being inert players, they appear to serve a dual role in AD pathogenesis, potentially offering defense mechanisms against pathology while also contributing to disease progression. This Review explores recent advancements in understanding the roles of oligodendrocytes and their myelin sheaths in the context of AD, shedding light on their complex interactions within the disease pathology.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Scheltens, P. et al. Alzheimer’s disease. Lancet 397, 1577–1590 (2021).
GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7, e105–e125 (2022).
Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016).
Jack, C. R. Jr. et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207–216 (2013).
Fagan, A. M. et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease. Sci. Transl. Med. 6, 226ra230 (2014).
Frisoni, G. B. et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat. Rev. Neurosci. 23, 53–66 (2022).
Rollo, J., Crawford, J. & Hardy, J. A dynamical systems approach for multiscale synthesis of Alzheimer’s pathogenesis. Neuron 111, 2126–2139 (2023).
Simons, M., Levin, J. & Dichgans, M. Tipping points in neurodegeneration. Neuron 111, 2954–2968 (2023).
De Strooper, B. & Karran, E. The cellular phase of Alzheimer’s disease. Cell 164, 603–615 (2016).
Mathys, H. et al. Single-cell transcriptomic analysis of Alzheimer’s disease. Nature 570, 332–337 (2019).
Mathys, H. et al. Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to Alzheimer’s disease pathology. Cell 186, 4365–4385 (2023).
Chen, W. T. et al. Spatial transcriptomics and in situ sequencing to study Alzheimer’s disease. Cell 182, 976–991 (2020).
Stadelmann, C., Timmler, S., Barrantes-Freer, A. & Simons, M. Myelin in the central nervous system: structure, function, and pathology. Physiol. Rev. 99, 1381–1431 (2019).
Marques, S. et al. Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. Science 352, 1326–1329 (2016).
Falcao, A. M. et al. Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. Nat. Med. 24, 1837–1844 (2018).
Timmler, S. & Simons, M. Grey matter myelination. Glia 67, 2063–2070 (2019).
Hill, R. A., Li, A. M. & Grutzendler, J. Lifelong cortical myelin plasticity and age-related degeneration in the live mammalian brain. Nat. Neurosci. 21, 683–695 (2018).
Hughes, E. G., Orthmann-Murphy, J. L., Langseth, A. J. & Bergles, D. E. Myelin remodeling through experience-dependent oligodendrogenesis in the adult somatosensory cortex. Nat. Neurosci. 21, 696–706 (2018).
Fard, M. K. et al. BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions. Sci. Transl. Med. 9, eaam7816 (2017).
Simons, M., Misgeld, T. & Kerschensteiner, M. A unified cell biological perspective on axon–myelin injury. J. Cell Biol. 206, 335–345 (2014).
Bergles, D. E., Roberts, J. D. B., Somogyi, P. & Jahr, C. E. Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus. Nature 405, 187–191 (2000).
Demerens, C. et al. Induction of myelination in the central nervous system by electrical activity. Proc. Natl Acad. Sci. USA 93, 9887–9892 (1996).
Gibson, E. M. et al. Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mammalian brain. Science 344, 1252304 (2014).
Paez, P. M. & Lyons, D. A. Calcium signaling in the oligodendrocyte lineage: regulators and consequences. Annu. Rev. Neurosci. 43, 163–186 (2020).
Chen, T. J. et al. In vivo regulation of oligodendrocyte precursor cell proliferation and differentiation by the AMPA-receptor subunit GluA2. Cell Rep. 25, 852–861 (2018).
Li, J., Miramontes, T. G., Czopka, T. & Monk, K. R. Synaptic input and Ca2+ activity in zebrafish oligodendrocyte precursor cells contribute to myelin sheath formation. Nat. Neurosci. 27, 219–231 (2024).
Lin, S.-c & Bergles, D. E. Synaptic signaling between GABAergic interneurons and oligodendrocyte precursor cells in the hippocampus. Nat. Neurosci. 7, 24–32 (2004).
Káradóttir, R., Cavelier, P., Bergersen, L. H. & Attwell, D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 438, 1162–1166 (2005).
Lu, T.-Y. et al. Norepinephrine modulates calcium dynamics in cortical oligodendrocyte precursor cells promoting proliferation during arousal in mice. Nat. Neurosci. 26, 1739–1750 (2023).
Fiore, F. et al. Norepinephrine regulates calcium signals and fate of oligodendrocyte precursor cells in the mouse cerebral cortex. Nat. Commun. 14, 8122 (2023).
Knowles, J. K. et al. Maladaptive myelination promotes generalized epilepsy progression. Nat. Neurosci. 25, 596–606 (2022).
Mitew, S. et al. Pharmacogenetic stimulation of neuronal activity increases myelination in an axon-specific manner. Nat. Commun. 9, 306 (2018).
Bonetto, G., Belin, D. & Karadottir, R. T. Myelin: a gatekeeper of activity-dependent circuit plasticity? Science 374, eaba6905 (2021).
Monje, M. Myelin plasticity and nervous system function. Annu. Rev. Neurosci. 41, 61–76 (2018).
Fields, R. D. White matter in learning, cognition and psychiatric disorders. Trends Neurosci. 31, 361–370 (2008).
Nave, K. A. Myelination and support of axonal integrity by glia. Nature 468, 244–252 (2010).
Snaidero, N. et al. Antagonistic functions of MBP and CNP establish cytosolic channels in CNS myelin. Cell Rep. 18, 314–323 (2017).
Funfschilling, U. et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485, 517–521 (2012).
Lee, Y. et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487, 443–448 (2012).
Saab, A. S. et al. Oligodendroglial NMDA receptors regulate glucose import and axonal energy metabolism. Neuron 91, 119–132 (2016).
Looser, Z. J. et al. Oligodendrocyte–axon metabolic coupling is mediated by extracellular K+ and maintains axonal health. Nat. Neurosci. 27, 433–448 (2024).
Mukherjee, C. et al. Oligodendrocytes provide antioxidant defense function for neurons by secreting ferritin heavy chain. Cell Metab. 32, 259–272 (2020).
Kenigsbuch, M. et al. A shared disease-associated oligodendrocyte signature among multiple CNS pathologies. Nat. Neurosci. 25, 876–886 (2022).
Pandey, S. et al. Disease-associated oligodendrocyte responses across neurodegenerative diseases. Cell Rep. 40, 111189 (2022).
Kaya, T. et al. CD8+ T cells induce interferon-responsive oligodendrocytes and microglia in white matter aging. Nat. Neurosci. 25, 1446–1457 (2022).
Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat. Med. 26, 131–142 (2020).
Haile, Y. et al. Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo. J. Neuroinflammation 12, 157 (2015).
Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712–716 (2016).
Kirby, L. et al. Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination. Nat. Commun. 10, 3887 (2019).
Habib, N. et al. Disease-associated astrocytes in Alzheimer’s disease and aging. Nat. Neurosci. 23, 701–706 (2020).
Zhang, P. et al. Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model. Nat. Neurosci. 22, 719–728 (2019).
Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169, 1276–1290 (2017).
Krasemann, S. et al. The TREM2–APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566–581 (2017).
Deczkowska, A. et al. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell 173, 1073–1081 (2018).
Park, H. et al. Single-cell RNA-sequencing identifies disease-associated oligodendrocytes in male APP NL-G-F and 5XFAD mice. Nat. Commun. 14, 802 (2023).
Andrews, S. J. et al. The complex genetic architecture of Alzheimer’s disease: novel insights and future directions. EBioMedicine 90, 104511 (2023).
Bertram, L., Lill, C. M. & Tanzi, R. E. The genetics of Alzheimer disease: back to the future. Neuron 68, 270–281 (2010).
Bateman, R. J. et al. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res. Ther. 3, 1 (2011).
Liu, C. C., Liu, C. C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106–118 (2013).
Serrano-Pozo, A., Das, S. & Hyman, B. T. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 20, 68–80 (2021).
Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8, 101–112 (2007).
Zhang, Y. et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89, 37–53 (2016).
Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929–11947 (2014).
Sharma, K. et al. Cell type- and brain region-resolved mouse brain proteome. Nat. Neurosci. 18, 1819–1831 (2015).
Gazestani, V. et al. Early Alzheimer’s disease pathology in human cortex involves transient cell states. Cell 186, 4438–4453 (2023).
Sasmita, A. O. et al. Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease model mice. Nat. Neurosci. 27, 1668–1674 (2024).
Rajani, R. M. et al. Selective suppression of oligodendrocyte-derived amyloid β rescues neuronal dysfunction in Alzheimer’s disease. PLoS Biol. 22, e3002727 (2024).
Guerreiro, R. J. et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 70, 78–84 (2013).
Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N. Engl. J. Med. 368, 107–116 (2013).
Ulrich, J. D., Ulland, T. K., Colonna, M. & Holtzman, D. M. Elucidating the role of TREM2 in Alzheimer’s disease. Neuron 94, 237–248 (2017).
Lewcock, J. W. et al. Emerging microglia biology defines novel therapeutic approaches for Alzheimer’s disease. Neuron 108, 801–821 (2020).
Kaneko, M., Sano, K., Nakayama, J. & Amano, N. Nasu–Hakola disease: the first case reported by Nasu and review: the 50th anniversary of Japanese Society of Neuropathology. Neuropathology 30, 463–470 (2010).
McNamara, N. B. et al. Microglia regulate central nervous system myelin growth and integrity. Nature 613, 120–129 (2023).
Djannatian, M. et al. Myelination generates aberrant ultrastructure that is resolved by microglia. J. Cell Biol. 222, e202204010 (2023).
Munro, D. A. D. et al. Microglia protect against age-associated brain pathologies. Neuron 112, 2732–2748 (2024).
Chadarevian, J. P. et al. Therapeutic potential of human microglia transplantation in a chimeric model of CSF1R-related leukoencephalopathy. Neuron 112, 2686–2707 (2024).
Blanchard, J. W. et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature 611, 769–779 (2022).
Cheng, G. W.-Y. et al. Apolipoprotein E ε4 mediates myelin breakdown by targeting oligodendrocytes in sporadic Alzheimer disease. J. Neuropathol. Exp. Neurol. 81, 717–730 (2022).
Saher, G. et al. High cholesterol level is essential for myelin membrane growth. Nat. Neurosci. 8, 468–475 (2005).
Camargo, N. et al. Oligodendroglial myelination requires astrocyte-derived lipids. PLoS Biol. 15, e1002605 (2017).
Dean, D. C. 3rd et al. Association of amyloid pathology with myelin alteration in preclinical Alzheimer disease. JAMA Neurol. 74, 41–49 (2017).
Protas, H. D. et al. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol. 70, 320–325 (2013).
Reiman, E. M. et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc. Natl Acad. Sci. USA 101, 284–289 (2004).
Nasrabady, S. E., Rizvi, B., Goldman, J. E. & Brickman, A. M. White matter changes in Alzheimer’s disease: a focus on myelin and oligodendrocytes. Acta Neuropathol. Commun. 6, 22 (2018).
Moghekar, A. et al. Cerebral white matter disease is associated with Alzheimer pathology in a prospective cohort. Alzheimers Dement. 8, S71–S77 (2012).
Roseborough, A., Ramirez, J., Black, S. E. & Edwards, J. D. Associations between amyloid β and white matter hyperintensities: a systematic review. Alzheimers Dement. 13, 1154–1167 (2017).
Brickman, A. M. et al. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch. Neurol. 69, 1621–1627 (2012).
Araque Caballero, M. Á. et al. White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease. Brain 141, 3065–3080 (2018).
Tosto, G., Zimmerman, M. E., Carmichael, O. T., Brickman, A. M. & Alzheimer’s Disease Neuroimaging Initiative. Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities. JAMA Neurol. 71, 872–877 (2014).
Brickman, A. M. et al. APOE ε4 and risk for Alzheimer’s disease: do regionally distributed white matter hyperintensities play a role? Alzheimers Dement. 10, 619–629 (2014).
Lee, S. et al. White matter hyperintensities are a core feature of Alzheimer’s disease: evidence from the Dominantly Inherited Alzheimer Network. Ann. Neurol. 79, 929–939 (2016).
Ryan, N. S. et al. Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer’s disease. Neurobiol. Aging 36, 3140–3151 (2015).
Brun, A. & Englund, E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 19, 253–262 (1986).
Simpson, J. E. et al. White matter lesions in an unselected cohort of the elderly: astrocytic, microglial and oligodendrocyte precursor cell responses. Neuropathol. Appl. Neurobiol. 33, 410–419 (2007).
Behrendt, G. et al. Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia 61, 273–286 (2013).
Gagyi, E. et al. Decreased oligodendrocyte nuclear diameter in Alzheimer’s disease and Lewy body dementia. Brain Pathol. 22, 803–810 (2012).
Desai, M. K., Guercio, B. J., Narrow, W. C. & Bowers, W. J. An Alzheimer’s disease-relevant presenilin-1 mutation augments amyloid-β-induced oligodendrocyte dysfunction. Glia 59, 627–640 (2011).
Chen, J. F. et al. Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer’s disease. Neuron 109, 2292–2307 (2021).
Sowell, E. R. et al. Mapping cortical change across the human life span. Nat. Neurosci. 6, 309–315 (2003).
Bethlehem, R. A. I. et al. Brain charts for the human lifespan. Nature 604, 525–533 (2022).
Prins, N. D. & Scheltens, P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat. Rev. Neurol. 11, 157–165 (2015).
Brouwer, R. M. et al. Genetic variants associated with longitudinal changes in brain structure across the lifespan. Nat. Neurosci. 25, 421–432 (2022).
Safaiyan, S. et al. Age-related myelin degradation burdens the clearance function of microglia during aging. Nat. Neurosci. 19, 995–998 (2016).
Peters, A. The effects of normal aging on myelin and nerve fibers: a review. J. Neurocytol. 31, 581–593 (2002).
Bartzokis, G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease. Neurobiol. Aging 25, 5–18 (2004).
Toyama, B. H. et al. Identification of long-lived proteins reveals exceptional stability of essential cellular structures. Cell 154, 971–982 (2013).
Fornasiero, E. F. et al. Precisely measured protein lifetimes in the mouse brain reveal differences across tissues and subcellular fractions. Nat. Commun. 9, 4230 (2018).
Collins-Praino, L. E. et al. Soluble amyloid β levels are elevated in the white matter of Alzheimer’s patients, independent of cortical plaque severity. Acta Neuropathol. Commun. 2, 83 (2014).
Depp, C. et al. Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease. Nature 618, 349–357 (2023).
Kaji, S. et al. Apolipoprotein E aggregation in microglia initiates Alzheimer’s disease pathology by seeding β-amyloidosis. Immunity 57, 2651–2668 (2024).
Schäffner, E. et al. Myelin insulation as a risk factor for axonal degeneration in autoimmune demyelinating disease. Nat. Neurosci. 26, 1218–1228 (2023).
Groh, J. et al. Microglia-mediated demyelination protects against CD8+ T cell-driven axon degeneration in mice carrying PLP defects. Nat. Commun. 14, 6911 (2023).
Traka, M., Podojil, J. R., McCarthy, D. P., Miller, S. D. & Popko, B. Oligodendrocyte death results in immune-mediated CNS demyelination. Nat. Neurosci. 19, 65–74 (2016).
Kedia, S. et al. T cell-mediated microglial activation triggers myelin pathology in a mouse model of amyloidosis. Nat. Neurosci. 27, 1468–1474 (2024).
Kang, S. H. et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 16, 571–579 (2013).
Ferreira, S. et al. Amyloidosis is associated with thicker myelin and increased oligodendrogenesis in the adult mouse brain. J. Neurosci. Res. 98, 1905–1932 (2020).
Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1991).
Braak, H. & Del Tredici, K. Alzheimer’s disease: pathogenesis and prevention. Alzheimers Dement. 8, 227–233 (2012).
Hughes, E. G., Kang, S. H., Fukaya, M. & Bergles, D. E. Oligodendrocyte progenitors balance growth with self-repulsion to achieve homeostasis in the adult brain. Nat. Neurosci. 16, 668–676 (2013).
Micheva, K. D. et al. A large fraction of neocortical myelin ensheathes axons of local inhibitory neurons. eLife 5, e15784 (2016).
Collins, C. E., Airey, D. C., Young, N. A., Leitch, D. B. & Kaas, J. H. Neuron densities vary across and within cortical areas in primates. Proc. Natl Acad. Sci. USA 107, 15927–15932 (2010).
Rubinski, A. et al. Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease. Alzheimers Res. Ther. 14, 139 (2022).
Bechler, M. E., Swire, M. & Ffrench-Constant, C. Intrinsic and adaptive myelination—a sequential mechanism for smart wiring in the brain. Dev. Neurobiol. 78, 68–79 (2018).
Knowles, J. K., Batra, A., Xu, H. & Monje, M. Adaptive and maladaptive myelination in health and disease. Nat. Rev. Neurol. 18, 735–746 (2022).
Bengtsson, S. L. et al. Extensive piano practicing has regionally specific effects on white matter development. Nat. Neurosci. 8, 1148–1150 (2005).
McKenzie, I. A. et al. Motor skill learning requires active central myelination. Science 346, 318–322 (2014).
Xiao, L. et al. Rapid production of new oligodendrocytes is required in the earliest stages of motor-skill learning. Nat. Neurosci. 19, 1210–1217 (2016).
Sampaio-Baptista, C. et al. Motor skill learning induces changes in white matter microstructure and myelination. J. Neurosci. 33, 19499–19503 (2013).
Liu, J. et al. Impaired adult myelination in the prefrontal cortex of socially isolated mice. Nat. Neurosci. 15, 1621–1623 (2012).
Makinodan, M., Rosen, K. M., Ito, S. & Corfas, G. A critical period for social experience-dependent oligodendrocyte maturation and myelination. Science 337, 1357–1360 (2012).
Acknowledgements
The work was supported by grants from the German Research Foundation (408885537-TRR 274, SyNergy Excellence Cluster, EXC2145, Projekt ID390857198), the ERC (Advanced Grant), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation and the Chan Zuckerberg Initiative grant.
Author information
Authors and Affiliations
Contributions
M.S. and S.K. conceived the theme, scope and structure of the Review, wrote the manuscript and drafted the figures.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Neuroscience thanks Siddharthan Chandran, Evan Macosko, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kedia, S., Simons, M. Oligodendrocytes in Alzheimer’s disease pathophysiology. Nat Neurosci 28, 446–456 (2025). https://doi.org/10.1038/s41593-025-01873-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41593-025-01873-x
